Opportunities in Europe, China, and Developing Nations Being Pursued HALIFAX, June 29 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) a global market leader in premium rapid diagnostic solutions, announced today that it has expanded its global sales team in order to capitalize on market penetration opportunities from recently completed key regulatory approvals. The expansion includes two new regional account managers dedicated to the Europe/Middle East and Latin America markets. Jaime Carreno and Pierre Sevigny together bring over 25 years of experience selling medical and technical products in these markets to the MedMira team. "We are very pleased to have these individuals on board and dedicated to leveraging sales opportunities in these important regions," said Hermes Chan, President & COO, MedMira Inc. "Ramping up our sales capabilities will enable us to better meet the needs of distributors and customers in critical global markets, like Latin America and Europe." After receiving CE Mark in early 2006 for its MiraCare(TM) Rapid HIV Antibody Test (MiraCare HIV), MedMira strategically selected countries in which to register with the Competent Authority, governing bodies within each member country regulating the sale of medical devices. MedMira's Regulatory Team has completed 13 registrations, the final step in the regulatory process, and will continue to pursue registrations in strategic country markets where sales opportunities exist. In Asia, MedMira has engaged MediServe Inc., a leading consulting group to head-up the company's sales and marketing activities in that region. MediServe is a partnership of project managers, medical doctors and healthcare practitioners, each with over 10 years of marketing and healthcare experience in Asia. The partners have a strong track record of serving international players such as Merck and their strengths include sales and distribution channel management and outsourcing business projects. MediServe was on-site at MedMira corporate headquarters in Halifax early this month to receive in-depth product training and finalize plans to launch MedMira's recently approved whole blood rapid HIV test in China. In April 2006, MedMira received a fast- tracked approval for the first and only whole blood rapid HIV test available in China. This approval enables MediServe to quickly capitalize on a key competitive advantage for MedMira in the China market. "With this latest whole blood approval and our new on-the-ground sales and marketing team in place, the timing is right to create a unique niche market for MedMira in China," said Chan. "We will also turn our attention to increasing MedMira's presence in developing nations, becoming part of their large scale testing programs." Richard Van Maanen, a biotechnology consultant and a former sales and marketing executive with another leading diagnostics manufacturer has been engaged by MedMira. Mr. Van Maanen will focus on increasing MedMira's profile with the international agencies and non-government organizations (NGOs) that provide testing solutions and programs to Africa and other developing nations. He will also identify qualified distributors and initiate local product registrations for MedMira in the Sub-Saharan region. MedMira's new sales & marketing team members will be travelling to various countries in their respective territories in the coming months, seeking new distributors in untapped markets, managing distributor relationships and capitalizing on sales opportunities for MedMira products. Additionally, MedMira will be taking part in the American Association for Clinical Chemistry's Clinical Lab Expo, July 25-27 in Chicago and the XVI International AIDS Conference (AIDS 2006) in Toronto, August 13-18. AIDS 2006 is a biennial conference that draws members of the international scientific, political, and business communities together to discuss and develop strategies to fight HIV/AIDS. On the regulatory front, MedMira continues preparations to enter the US market with an over-the-counter (OTC) rapid HIV test. MedMira has submitted a proposed solution to the FDA and is ready to begin the market entry and regulatory process once the proposal is reviewed. MedMira's proposed US OTC solution is built on the company's solid experience in the Hong Kong OTC market, where it successfully launched its MiraCare HIV test in 2005. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA, the SFDA in the People's Republic of China and European Union have approved MedMira's Reveal(R) G2, MiraWell(R) and MiraCare(TM) rapid HIV tests, respectively. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. MiraCare(TM) is sold through MedMira's distributor network to pharmacies, hospitals and laboratories in the European Union. It is also available over- the-counter (OTC) in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office and joint venture manufacturing facility in Guilin, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail: ; Andrea Young, Corporate Communications, Tel. (902) 450-1588, Email:

Copyright